Camurus ABCAMRF 81 3-1 Month Momentum % is 5.45% as of Jul. 13, 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $83.52 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 1,389 Biotechnology companies, Camurus AB ranks better than 76.1% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-13), Camurus AB's 3-1 Month Momentum % is 5.45%.
The industry rank for Camurus AB's 3-1 Month Momentum % or its related term are showing as below:
CAMRF's 3-1 Month Momentum % is ranked better than 76.1% of 1389
companies
in the Biotechnology industry
Industry Median: -11.38
vs CAMRF: 5.45
Camurus AB (OTCPK:CAMRF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Camurus AB 3-1 Month Momentum % Related Terms
CAMRF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Camurus AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Camurus AB's 3-1 Month Momentum % falls into.
Camurus AB (OTCPK:CAMRF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a 3-1 Month Momentum % of 5.45% as of Jul. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #332 out of 1389 companies in the Biotechnology industry, placing it in the top 23.9%.
Is Camurus AB's 3-1 Month Momentum % too high?
Camurus AB's current 3-1 Month Momentum % is 5.45%. Based on the distribution chart, Camurus AB ranks #332 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #332 out of 1389 companies for 3-1 Month Momentum %. This places Camurus AB in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Camurus AB and its competitors. Camurus AB's current 3-1 Month Momentum % is 5.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.52, compared to a current price of $60.00 — trading 28.2% below its estimated fair value. The current 3-1 Month Momentum % is 5.45%. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current 3-1 Month Momentum % is 5.45% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28.2% below its estimated GF Value™ of $83.52.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
3-1 Month Momentum %: 5.45%
GF Value™: $83.52 vs. price of $60.00 (28.2% below fair value)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 